lung

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

3 months ago

Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…

3 months ago

Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community

SAN FRANCISCO, Sept. 06, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, Troper Wojcicki Philanthropies (TWP), and Lifebit today announced the…

4 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

September 04, 2025 20:00 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05,…

4 months ago

Wheres the Commitment? Provincial Silence on Big Tobacco Payouts Leaves Canadians Wondering if Lung Health Will be Left Behind, Says National Lung Health Alliance

TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- On Friday, August 29, the provinces and territories are expected to receive their initial…

4 months ago

Intas Pharmaceuticals Launches HETRONIFLY (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer

AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for…

5 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced…

7 months ago

MannKind to Highlight Data from Recent Pediatric and Adult Studiesof Inhaled Insulin (Afrezza) at American Diabetes Associations85th Scientific Sessions in Chicago, June 20-23

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the…

7 months ago

Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…

7 months ago